QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
LON:ROQ

Roquefort Therapeutics (ROQ) Share Forecast, Price & News

GBX 7.62
+0.12 (+1.60%)
(As of 09/28/2023 ET)
Compare
Today's Range
7.25
▼
7.70
50-Day Range
6
▼
9
52-Week Range
5.75
▼
9.40
Volume
319,082 shs
Average Volume
256,879 shs
Market Capitalization
£9.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsInsider TradesHeadlines

ROQ stock logo

About Roquefort Therapeutics (LON:ROQ) Stock

Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.

ROQ Price History

ROQ Stock News Headlines

September 27, 2023 | proactiveinvestors.com
Roquefort Therapeutics preparing targets for clinic as eyes commercial deals
September 27, 2023 | proactiveinvestors.com
Roquefort Therapeutics preparing targets for clinic as it eyes commercial deals
September 28, 2023 | Tradewins (Ad)
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
September 21, 2023 | americanbankingnews.com
Roquefort Therapeutics (LON:ROQ) Stock Price Up 9.8%
August 17, 2023 | finance.yahoo.com
Roquefort Therapeutics seeks to lock in future value with anti-cancer therapeutic patents
August 9, 2023 | finance.yahoo.com
Roquefort Therapeutics making headway with siRNA
June 29, 2023 | proactiveinvestors.com
Roquefort Therapeutics highlights significant progress at AGM
June 22, 2023 | proactiveinvestors.com
Roquefort Therapeutics hails significant pre-clinical results
September 28, 2023 | Tradewins (Ad)
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
June 22, 2023 | marketwatch.com
Roquefort Therapeutics Makes Progress on Cancer Treatment
June 16, 2023 | finance.yahoo.com
Roquefort Therapeutics returns to the market with new study data
June 13, 2023 | marketwatch.com
Roquefort Therapeutics' Anti-Cancer MRNA Study Showed Positive Results
June 7, 2023 | marketwatch.com
Roquefort Therapeutics Resumes Trading After Publishing 2022 Results
June 5, 2023 | proactiveinvestors.com
Roquefort Therapeutics eyes second half progress
March 13, 2023 | proactiveinvestors.com
Roquefort Therapeutics has no exposure to SVB
March 8, 2023 | proactiveinvestors.com
Roquefort Therapeutics says new mRNA platform "fits very well"
March 8, 2023 | proactiveinvestors.com
Roquefort develops a fifth programme using a technology pioneered by Moderna and BioNTech
March 6, 2023 | proactiveinvestors.com
Roquefort Therapeutics establishes scientific advisory board
February 22, 2023 | lse.co.uk
Roquefort Thera Regulatory News
February 21, 2023 | barrons.com
Roquefort Therapeutics PLC
February 20, 2023 | proactiveinvestors.com
Roquefort Therapeutics inks Randox diagnostic deal
February 20, 2023 | proactiveinvestors.com
Roquefort Therapeutics inks first strategic licensing deal with diagnostics firm Randox
January 26, 2023 | finance.yahoo.com
Roquefort Therapeutics demonstrates initial safety in two antibody programmes
January 24, 2023 | proactiveinvestors.com
Roquefort Therapeutics demonstrates safety in two antibody programmes
January 24, 2023 | proactiveinvestors.com
Roquefort Therapeutics cancer drugs enjoy pre-clinical success
January 9, 2023 | proactiveinvestors.com
Roquefort Therapeutics CEO lays out strategy for 2023
January 9, 2023 | proactiveinvestors.com
Roquefort Therapeutics in out-licensing discussions with 'multiple' large bio-pharma companies
See More Headlines
Receive ROQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:ROQ
CUSIP
N/A
CIK
N/A
Web
www.roquefortinvest.com
Phone
44 20 3290 9339
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-1,620,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-28.62%
Return on Assets
-16.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.67
Quick Ratio
3.07

Sales & Book Value

Annual Sales
£637.00
Price / Sales
15,459.48
Cash Flow
GBX 5.10 per share
Price / Cash Flow
1.49
Book Value
GBX 6 per share
Price / Book
1.27

Miscellaneous

Outstanding Shares
129,150,000
Free Float
N/A
Market Cap
£9.85 million
Optionable
Not Optionable
Beta
-0.13
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Stephen Paul West B.Com (Age 50)
    CA, Exec. Chairman
    Comp: $118.31k
  • Mr. Trevor Ajanthan Reginald (Age 51)
    CEO & Exec. Director
    Comp: $284.1k
  • Prof. Martin J. Evans FRS
    Group Chief Scientific Officer & Exec. Director
  • Dr. Emma Morris
    Head of Pre-Clinical Research

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













ROQ Stock - Frequently Asked Questions

How have ROQ shares performed in 2023?

Roquefort Therapeutics' stock was trading at GBX 6.75 at the start of the year. Since then, ROQ shares have increased by 13.0% and is now trading at GBX 7.63.
View the best growth stocks for 2023 here.

What is Roquefort Therapeutics' stock symbol?

Roquefort Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "ROQ."

How do I buy shares of Roquefort Therapeutics?

Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Roquefort Therapeutics' stock price today?

One share of ROQ stock can currently be purchased for approximately GBX 7.63.

How much money does Roquefort Therapeutics make?

Roquefort Therapeutics (LON:ROQ) has a market capitalization of £9.85 million and generates £637.00 in revenue each year. The company earns £-1,620,000.00 in net income (profit) each year or GBX (0.02) on an earnings per share basis.

How can I contact Roquefort Therapeutics?

Roquefort Therapeutics' mailing address is Eccleston Yards, 25 Eccleston Place, London SW1W 9NF, United Kingdom. The official website for the company is www.roquefortinvest.com. The company can be reached via phone at 44 20 3290 9339.

This page (LON:ROQ) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -